This article describes how media sentiment toward psychedelic therapies rose sharply and then declined after recent regulatory disappointment.
Evidence
It discusses a analysis, validated against human raters, of 25 years of media articles from 2000 to 2025.
Caveat
The abstract summarizes media sentiment trends rather than testing psychedelic therapies' clinical efficacy or safety directly.
Simplified
Psychedelics were used for centuries in healing and spiritual rituals, long before the mid-20th century when they became subjects of biomedical research. Although initial trials generated optimism, these were quickly overshadowed by sensationalist media coverage and political backlash. Following decades of inactivity, research on compounds including 3,4-methylenedioxymethamphetamine (MDMA) has resurged, along with the media attention. Investigating this growing interest, Bender et al employed a , validated against human raters, to analyse 25 years of media articles (2000-2025), quantifying trends in sentiment towards psychedelic therapies. Findings showed a dramatic increase in coverage, with positive sentiment peaking in 2020 followed by a significant decline from 2024, coinciding with the U.S. Food and Drug Administration's decision not to approve MDMA-assisted therapy for post-traumatic stress disorder, and echoing the dynamics of the 1960s. The authors emphasise that sustained progress in the field will require reliance on scientific evidence to advance therapeutic applications.
Key numbers
501%
Increase in Media Coverage
Increase in media articles about psychedelics from 2000 to 2025.
80.8%
Positive Sentiment Peak
Average sentiment score in 2020 regarding psychedelic therapeutic use.
85.5%
Therapeutic Framing Shift
Percentage of articles framing psychedelics therapeutically from 2020 to 2025.
Full Text
We can’t show the full text here under this license.
